+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

End Stage Renal Disease Market Size, Share & Trends Analysis Report By Treatment (Transplant, Dialysis), By Region (APAC, North America, MEA, Europe, Latin America), And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 171 Pages
  • May 2023
  • Region: Global
  • Grand View Research
  • ID: 5626316
Description Jump to:
The global end-stage renal disease market size is anticipated to reach USD 261.64 billion by 2030, registering a CAGR of 13.0% from 2023 to 2030. Increasing number of patients suffering from kidney failure, rapid increase in the volume of hospitals & urgent care centers, and growing hospital admission rates are among the few factors propelling the market growth. Chronic Kidney Disease (CKD) is one of the major causes of increasing kidney failure rates among patients. According to the CDC, it is estimated that more than 37 million people in the U. S. suffer from CKD, whereas globally more than 500 million people (12-18% of the world population) are affected. As a result, increasing the demand for dialysis or kidney transplant. The COVID-19 pandemic has impacted the healthcare industry and people suffering from ESRD are at a higher risk of contracting this virus, as they have to visit the hospitals often for dialysis. Center-based hemodialysis is the main re
nal replacement medium in most countries, with almost 90% of the ESRD population opting for it. Hemodialysis patients have to stay in hospitals for 4 hours minimum, 3 times a week, and come in frequent contact with the medical staff and other patients. All these factors increase their risk of infection. Technological advancements in the treatment of renal failure are another factor expediting the market growth for ESRD. For instance, the innovation of Wearable Artificial Kidney (WAK) technologies, a portable dialysis device designed to enable patients to live a healthier life as it controls blood pressure, improves clearance of wastes from the blood, and allows ESRD or CKD patients to a less strict diet, and results in lower fluid weight gain in addition to lowered stress on the heart. Thus, technical advancements in WAK have the potential to reduce mortality in dialysis patients, which thereby improves an ESRD patient’s quality of life. The WAK prototypes designed and patented by innovative firms have been a
pproved for human clinical trials by the U. S. FDA in 2016.

End Stage Renal Disease Market Report Highlights

  • The dialysis segment dominated the global ESRD market in 2022 and accounted for the maximum share of more than 77.5% of the total revenue owing to its ease of use and emergency convenience
  • This segment is further sub-segmented into peritoneal, hemodialysis, and wearable artificial kidney
  • Asia Pacific dominated the regional market in 2022 and accounted for the largest revenue share of more than 37.4% and will expand further at the fastest CAGR from 2023 to 2030
  • This growth can be attributed to the large population of patients with CKD/ESRD, and the greater incidence of hypertension and diabetes in the continent

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Treatment
1.1.3 Regional Scope
1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume Price Analysis (Model 2)
1.6.2.1 Approach 2: Volume Price Analysis
1.7 List Of Secondary Sources
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Snapshot
2.3 Competitive Analysis Snapshot
Chapter 3 End Stage Renal Disease Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis
3.4 User Perspective Analysis
3.4.1 Consumer Behavior Analysis
3.4.2 Market Influencer Analysis
3.5 List Of Key End Users
3.6 Regulatory Framework
3.7 Market Dynamics
3.7.1 Market Driver Analysis
3.7.1.1 Growing prevalence of diabetes and hypertension
3.7.1.2 Introduction of technologically advanced products
3.7.1.3 Increasing number of patients suffering from chronic kidney disease
3.7.2 Market Restraints Analysis
3.7.2.1 Risk Of Complications
3.7.2.2 Stringent Regulatory Policies For Dialysis Products
3.8 End Stage Renal Disease: Market Analysis Tools
3.8.1 Industry Analysis - Porter’s
3.8.2 Swot Analysis, By Pest
Chapter 4 End Stage Renal Disease Market: Segment Analysis, By Treatment, 2018 - 2030 (USD Million)
4.1 Definition and Scope
4.2 Treatment Market Share Analysis, 2022 & 2030
4.3 Segment Dashboard
4.4 Global End Stage Renal Disease Market, by Treatment, 2018 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.5.1 Dialysis
4.5.1.1 Dialysis Market, 2018 - 2030 (USD Million)
4.5.2 Transplant
4.5.2.1 Transplant Market, 2018 - 2030 (USD Million)
Chapter 5 End Stage Renal Disease Market: Regional Market Analysis, By Treatment, 2018 - 2030 (USD Million)
5.1. Regional market share analysis, 2022 & 2030
5.2. Regional Marketplace: Key Takeaways
5.3. North America
5.3.6. SWOT Analysis
5.3.2. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.3.3. U.S.
5.3.3.1. Country Dynamics
5.3.3.2. Country Variables
5.3.3.3. Competitive Landscape
5.3.3.4. Regulatory/Reimbursement Framework
5.3.3.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.3.4. Canada
5.3.4.1. Country Dynamics
5.3.4.2. Country Variables
5.3.4.3. Competitive Landscape
5.3.4.4. Regulatory/Reimbursement Framework
5.3.4.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.4. Europe
5.4.1. SWOT Analysis
5.4.2. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.4.3. UK
5.4.3.1. Country Dynamics
5.4.3.2. Country Variables
5.4.3.3. Competitive Landscape
5.4.3.4. Regulatory/Reimbursement Framework
5.4.3.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.4.4. Germany
5.4.4.1. Country Dynamics
5.4.4.2. Country Variables
5.4.4.3. Competitive Landscape
5.4.4.4. Regulatory/Reimbursement Framework
5.4.4.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.4.5. France
5.4.5.1. Country Dynamics
5.4.5.2. Country Variables
5.4.5.3. Competitive Landscape
5.4.5.4. Regulatory/Reimbursement Framework
5.4.5.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.4.6. Italy
5.4.6.1. Country Dynamics
5.4.6.2. Country Variables
5.4.6.3. Competitive Landscape
5.4.6.4. Regulatory/Reimbursement Framework
5.4.6.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.4.7. Spain
5.4.7.1. Country Dynamics
5.4.7.2. Country Variables
5.4.7.3. Competitive Landscape
5.4.7.4. Regulatory/Reimbursement Framework
5.4.7.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.4.8. Denmark
5.4.8.1. Country Dynamics
5.4.8.2. Country Variables
5.4.8.3. Competitive Landscape
5.4.8.4. Regulatory/Reimbursement Framework
5.4.8.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.4.9. Sweden
5.4.9.1. Country Dynamics
5.4.9.2. Country Variables
5.4.9.3. Competitive Landscape
5.4.9.4. Regulatory/Reimbursement Framework
5.4.9.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.4.10. Norway
5.4.10.1. Country Dynamics
5.4.10.2. Country Variables
5.4.10.3. Competitive Landscape
5.4.10.4. Regulatory/Reimbursement Framework
5.4.10.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.5. Asia Pacific
5.5.6. SWOT Analysis
5.5.2. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.5.3. Japan
5.5.3.1. Country Dynamics
5.5.3.2. Country Variables
5.5.3.3. Competitive Landscape
5.5.3.4. Regulatory/Reimbursement Framework
5.5.3.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.5.4. China
5.5.4.1. Country Dynamics
5.5.4.2. Country Variables
5.5.4.3. Competitive Landscape
5.5.4.4. Regulatory/Reimbursement Framework
5.5.4.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.5.5. India
5.5.5.1. Country Dynamics
5.5.5.2. Country Variables
5.5.5.3. Competitive Landscape
5.5.5.4. Regulatory/Reimbursement Framework
5.5.5.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.5.6. Australia
5.5.6.1. Country Dynamics
5.5.6.2. Country Variables
5.5.6.3. Competitive Landscape
5.5.6.4. Regulatory/Reimbursement Framework
5.5.6.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.5.7. Thailand
5.5.7.1. Country Dynamics
5.5.7.2. Country Variables
5.5.7.3. Competitive Landscape
5.5.7.4. Regulatory/Reimbursement Framework
5.5.7.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.5.8. South Korea
5.5.8.1. Country Dynamics
5.5.8.2. Country Variables
5.5.8.3. Competitive Landscape
5.5.8.4. Regulatory/Reimbursement Framework
5.5.8.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.6. Latin America
5.6.1. SWOT Analysis
5.6.2. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.6.3. Brazil
5.6.3.1. Country Dynamics
5.6.3.2. Country Variables
5.6.3.3. Competitive Landscape
5.6.3.4. Regulatory/Reimbursement Framework
5.6.3.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.6.4. Mexico
5.6.4.1. Country Dynamics
5.6.4.2. Country Variables
5.6.4.3. Competitive Landscape
5.6.4.4. Regulatory/Reimbursement Framework
5.6.4.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.6.5. Argentina
5.6.5.1. Country Dynamics
5.6.5.2. Country Variables
5.6.5.3. Competitive Landscape
5.6.5.4. Regulatory/Reimbursement Framework
5.6.5.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.7. MEA
5.7.1. SWOT Analysis
5.7.2. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.7.3. South Africa
5.7.3.1. Country Dynamics
5.7.3.2. Country Variables
5.7.3.3. Competitive Landscape
5.7.3.4. Regulatory/Reimbursement Framework
5.7.3.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.7.4. Saudi Arabia
5.7.4.1. Country Dynamics
5.7.4.2. Country Variables
5.7.4.3. Competitive Landscape
5.7.4.4. Regulatory/Reimbursement Framework
5.7.4.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.7.5. UAE
5.7.5.1. Country Dynamics
5.7.5.2. Country Variables
5.7.5.3. Competitive Landscape
5.7.5.4. Regulatory/Reimbursement Framework
5.7.5.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
5.7.6. Kuwait
5.7.6.1. Country Dynamics
5.7.6.2. Country Variables
5.7.6.3. Competitive Landscape
5.7.6.4. Regulatory/Reimbursement Framework
5.7.6.5. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
Chapter 6 End Stage Renal Disease Market - Competitive Analysis
6.1 Recent Developments & Impact Analysis, By Key Market Participants
6.2 Company Categorization
6.2.1 Innovators
6.2.2 Market Leaders
6.3 Vendor Landscape
6.3.1 Key Customers
6.3.2 Key Company Market Share Analysis, 2021
6.3.3 Major Deals And Strategic Alliances
6.3.3.1 New Product Launch
6.3.3.2 Expansion
6.3.3.3 Acquistion
6.3.3.4 Marketing & Promotions
6.3.4 Market Entry Strategies
6.4 Public Companies
6.4.1 Company Market Position Analysis
6.4.2 Competitive Dashboard Analysis
6.4.2.1 Market Differentiators
6.5 Private Companies
6.5.1 List Of Key Emerging Companies
6.5.3 Regional Network Map
6.5.4 Company Market Position Analysis
6.6 Company Profiles
6.6.1 Medtronic
6.6.1.1 Company Overview
6.6.1.2 Financial Performance
6.6.1.3 Product Benchmarking
6.6.1.4 Strategic Initiatives
6.6.2 Fresenius Medical Care Ag & Co. Kgaa
6.6.2.1 Company Overview
6.6.2.2 Financial Performance
6.6.2.3 Product/Service Benchmarking
6.6.2.4 Strategic Initiatives
6.6.3 B. Braun Melsungen Ag
6.6.3.1 Company Overview
6.6.3.2 Financial Performance
6.6.3.3 Product/Service Benchmarking
6.6.4 Baxter International, Inc.
6.6.4.1 Company Overview
6.6.4.2 Financial Performance
6.6.4.3 Product Benchmarking
6.6.4.4 Strategic Initiatives
6.6.5 Asahi Kasei Medical Co., Ltd.
6.6.5.1 Company Overview
6.6.5.2 Financial Performance
6.6.5.3 Product Benchmarking
6.6.5.4 Strategic Initiatives
6.6.6 Cantel Medical
6.6.6.1 Company overview
6.6.6.2 Financial performance
6.6.6.3 Product benchmarking
6.6.6.4 Strategic initiatives
6.6.7 BD
6.6.7.1 Company overview
6.6.7.2 Financial performance
6.6.7.3 Product benchmarking
6.6.7.4 Strategic initiatives
6.6.8 NIKKISO CO., LTD
6.6.8.1 Company overview
6.6.8.2 Financial performance
6.6.8.3 Product benchmarking
6.6.8.4 Strategic initiatives
6.6.9 JMS CO. LTD
6.6.9.1 Company overview
6.6.9.2 Financial performance
6.6.9.3 Product benchmarking
6.6.9.4 Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviation
Table 3 North America end stage renal disease market, by country, 2018 - 2030 (USD Million)
Table 4 North America end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 5 U.S. end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 6 Canada end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 7 Europe end stage renal disease market, by country, 2018 - 2030 (USD Million)
Table 8 Europe end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 9 U.K. end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 10 Germany end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 11 France end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 12 Italy end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 13 Spain end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 14 Denmark end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 15 Norway end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 16 Sweden end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 17 Asia Pacific end stage renal disease market, by country, 2018 - 2030 (USD Million)
Table 18 Asia Pacific end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 19 China end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 20 India end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 21 South Korea end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 22 Australia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 23 Japan end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 24 Thailand end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 25 Latin America end stage renal disease market, by country, 2018 - 2030 (USD Million)
Table 26 Latin America end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 27 Brazil end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 28 Mexico end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 29 Argentina end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 30 Colombia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 31 Middle East & Africa end stage renal disease market, by country, 2018 - 2030 (USD Million)
Table 32 Middle East & Africa end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 33 South Africa end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 34 South Arabia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 35 UAE end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 36 Kuwait end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 End stage renal disease market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market outlook (2022)
Fig. 10 Segment Outlook
Fig. 11 Strategy framework
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Consumer behavior analysis
Fig. 14 Market driver relevance analysis (Current & future impact)
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Porter’s five forces analysis
Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 18 End Stage Renal Disease market: Treatment movement analysis
Fig. 19 Segment dashboard
Fig. 20 End Stage Renal Disease market treatment outlook: Key takeaways
Fig. 21 Dialysis market, 2018 - 2030 (USD Million)
Fig. 22 Transplantation market, 2018 - 2030 (USD Million)
Fig. 23 End Stage Renal Disease market: End use movement analysis
Fig. 24 Regional outlook, 2022 & 2030
Fig. 25 Regional market dashboard
Fig. 26 Regional market place: Key takeaways
Fig. 27 North America end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 28 U.S. end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 29 Canada end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 30 Europe end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 31 U.K. End Stage Renal Disease market, 2018 - 2030 (USD Million)
Fig. 32 Germany end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 33 France end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 34 Italy end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 35 Spain end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 36 Denmark end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 37 Sweden end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 38 Norway end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 39 Asia Pacific end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 40 Japan end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 41 China (Mainland) end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 42 India end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 43 Australia end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 44 South Korea end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 45 Thailand end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 46 Latin America end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 47 Brazil end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 48 Mexico end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 49 Argentina end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 50 Colombia end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 51 MEA end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 52 South Africa end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 53 Saudi Arabia end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 54 UAE end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 55 Kuwait end stage renal disease market, 2018 - 2030 (USD Million)
Fig. 56 Company market share analysis, 2022
Fig. 57 Strategy mapping
Fig. 58 Market differentiators
Fig. 59 Regional network map

Companies Mentioned

  • Medtronic
  • Fresenius Medical Care Ag & Co. Kgaa
  • B. Braun Melsungen Ag
  • Baxter International, Inc.
  • Asahi Kasei Medical Co., Ltd.
  • Cantel Medical
  • BD
  • NIKKISO CO., LTD
  • JMS CO. LTD

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages171
PublishedMay 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 99.1 Billion
Forecasted Market Value ( USD ) by 2030 $ 261.64 Billion
Compound Annual Growth Rate13.0%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

End Stage Renal Disease Market by Treatment, Diagnosis, End-User - Global Forecast 2025-2030 - Product Image

End Stage Renal Disease Market by Treatment, Diagnosis, End-User - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
End-Stage Renal Disease (ESRD) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

End-Stage Renal Disease (ESRD) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
End-Stage Renal Disease - Global Strategic Business Report - Product Image

End-Stage Renal Disease - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
End-Stage Renal Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

End-Stage Renal Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 137 Pages
  • Global
From
End Stage Renal Disease Market Analysis & Forecast to 2024-2034 - Product Image

End Stage Renal Disease Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.